Form 144 Filer Information

FORM 144

144: Filer Information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

| Filer CIK | 0001291937 | | |
|---|--|--|--|
| Filer CCC | XXXXXXXX | | |
| Is this a LIVE or TEST Filing? | ■ LIVE TEST | | |
| Submission Contact Information | Submission Contact Information | | |
| Name | | | |
| Phone | | | |
| E-Mail Address | | | |
| 144: Issuer Information | | | |
| Name of Issuer | Adaptimmune Therapeutics PLC | | |
| SEC File Number | 001-37368 | | |
| Address of Issuer | 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE UNITED KINGDOM OX14 4RX | | |
| Phone | 44 1235 430000 | | |
| Name of Person for Whose Account the Securities are To Be Sold | Bertrand William C JR | | |
| the securities are to be sold but also as to a | (a) of Rule 144. Information is to be given not only as to the person for whose account ill other persons included in that definition. In addition, information shall be given as to red by paragraph (e) of Rule 144 to be aggregated with sales for the account of the | | |
| Relationship to Issuer | Chief Operating Officer | | |
| 144: Securities Information | | | |
| Title of the Class of Securities To Be Sold | | | |
| | American Depositary Shares | | |
| Name and Address of the Broker | American Depositary Shares Maxim Group 300 Park Ave 16th Floor NEW YORK NY 10022 | | |
| Name and Address of the Broker Number of Shares or Other Units To Be Sold | Maxim Group 300 Park Ave 16th Floor NEW YORK NY | | |
| Number of Shares or Other Units To Be | Maxim Group 300 Park Ave 16th Floor NEW YORK NY 10022 | | |
| Number of Shares or Other Units To Be Sold | Maxim Group 300 Park Ave 16th Floor NEW YORK NY 10022 | | |
| Number of Shares or Other Units To Be Sold Aggregate Market Value Number of Shares or Other Units | Maxim Group 300 Park Ave 16th Floor NEW YORK NY 10022 9739 5726.00 | | |
| Number of Shares or Other Units To Be Sold Aggregate Market Value Number of Shares or Other Units Outstanding | Maxim Group 300 Park Ave 16th Floor NEW YORK NY 10022 9739 5726.00 255880000 | | |

| Title of the Class of Securities To Be Sold | American Depositary Shares |
|---|---|
| Name and Address of the Broker | Maxim Group 300 Park Ave 16th Floor NEW YORK NY 10022 |
| Number of Shares or Other Units To Be Sold | 9803 |
| Aggregate Market Value | 5635.00 |
| Number of Shares or Other Units Outstanding | 255880000 |
| Approximate Date of Sale | 01/15/2025 |
| Name the Securities Exchange | NASDAQ |

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

| Title of the Class | American Depositary Shares |
|-----------------------------------|-----------------------------------|
| Date you Acquired | 01/13/2025 |
| Nature of Acquisition Transaction | Sell to cover exercise (cashless) |
| Name of Person from Whom Acquired | Adaptimmune Therapeutics plc |
| Is this a Gift? | Date Donor Acquired |
| Amount of Securities Acquired | 9739 |
| Date of Payment | 01/13/2025 |
| Nature of Payment | COMPENSATION |

If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

144: Securities To Be Sold

| Title of the Class | American Depositary Shares |
|-----------------------------------|-----------------------------------|
| Date you Acquired | 01/15/2025 |
| Nature of Acquisition Transaction | Sell to cover exercise (cashless) |
| Name of Person from Whom Acquired | Adaptimmune Therapeutics plc |
| Is this a Gift? | Date Donor Acquired |
| Amount of Securities Acquired | 9803 |
| Date of Payment | 01/15/2025 |
| Nature of Payment | COMPENSATION |

If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months Nothing to Report 144: Remarks and Signature Remarks Date of Notice 01/15/2025

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature Bertrand William C JR

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)